Abstract
Ninety-one lung cancer patients were evaluated to determine the usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastases and also to investigate their clinical usefulness as an adjunct to bone scintigraphy. Both bone resorption markers, ICTP and fDPD, and bone formation markers, Al-p, BAL, PICP and BGP, were evaluated in 47 patients with and 44 without bone metastasis. The patients with bone metastasis were classified according to the bone metastatic burden, and they were also separately classified into groups according to the course of the bone metastasis. ICTP, fDPD, Al-p and BAL were significantly elevated (P < 0.001) in patients with bone metastasis, but PICP and BGP were not. Receiver-operating characteristic (ROC) curves of these markers revealed that ICTP was most highly correlated with the diagnosis of bone metastasis. The sensitivity of ICTP (71.4%) and fDPD (61.0%) were good with high specificity. T scores of ICTP, fDPD and BAL tended to be higher at higher grades of bone metastasis. T-scores of ICTP, fDPD and BAL were elevated in the newly diagnosed cases and progressed cases, but the T-scores of ICTP and fDPD in those cases were higher than that of BAL. In the follow-up study, ICTP was well correlated with uncontrolled or controlled bone metastasis. Thus, bone resorption markers, especially ICTP, could be a good indicator of the progression and multiplicity of disease, and it could help in the follow-up and in the monitoring of therapy for bone metastasis from lung cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Aruga, A., Koizumi, M., Hotta, R. et al. Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer. Br J Cancer 76, 760–764 (1997). https://doi.org/10.1038/bjc.1997.458
Issue Date:
DOI: https://doi.org/10.1038/bjc.1997.458
This article is cited by
-
A meta-analysis survey of appropriate bone turnover markers in the detection of bone metastasis in lung cancer
International Journal of Clinical Oncology (2017)
-
Significance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasis
World Journal of Urology (2015)
-
Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis
Journal of Experimental & Clinical Cancer Research (2013)
-
Finding biomarkers for non-small cell lung cancer diagnosis and prognosis
Frontiers in Biology (2012)
-
The clinical importance of bone metabolic markers in detecting bone metastasis of lung cancer
International Journal of Clinical Oncology (2012)